New drug duo tested for Tough-to-Treat liver cancer
NCT ID NCT05644379
Summary
This study is testing whether combining two drugs, cadonilimab and regorafenib, can help control advanced liver cancer that has continued to grow despite at least one prior treatment. It will involve about 30 adults to see how well the combination works and how safe it is. The main goals are to see if tumors shrink, how long patients live without the cancer getting worse, and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA THAT HAS FAILED AT LEAST ONE PRIOR SYSTEMIC THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, 300308, China
Conditions
Explore the condition pages connected to this study.